Parathyroid hormone (1–84) and teriparatide in the treatment of postmenopausal osteoporosis

By Bogado1 César E   Massari2 Fabio E   Zanchetta3 José R  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 447-457

Future Medicine

Access to resources Recommend Favorite

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis

By Sellmeyer D.   Black D.   Palermo L.   Greenspan S.   Ensrud K.   Bilezikian J.   Rosen C.  

Osteoporosis International, Vol. 18, Iss. 7, 2007-07 ,pp. : 973-979

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of postmenopausal women with osteoporosis with PTH(1–84) for 36 months: treatment extension study

By Zanchetta José R.   Bogado Cesar E.   Cisari Carlo   Aslanidis Spyros   Greisen Hanna   Fox John   Lems Willem  

Current Medical Research and Opinion, Vol. 26, Iss. 11, 2010-11 ,pp. : 2627-2633

Informa Healthcare

Access to resources Recommend Favorite

Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis

By Migliore A.   Broccoli S.   Massafra U.   Bizzi E.   Frediani B.  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 467-473

Informa Healthcare

Access to resources Recommend Favorite

Effect of Parathyroid Hormone (hPTH[1-84]) Treatment on Bone Mass and Strength in Ovariectomized Rats

By Akhter M.P.   Kimmel D.B.   Recker R.R.  

Journal of Clinical Densitometry, Vol. 4, Iss. 1, 2001-01 ,pp. : 13-23

Humana Press, Inc

Access to resources Recommend Favorite